ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,232 | -42.0% | 443 | -55.7% | 0.00% | – |
| Q4 2022 | $15,920 | -0.5% | 1,000 | 0.0% | 0.00% | – |
| Q3 2022 | $16,000 | +14.3% | 1,000 | 0.0% | 0.00% | – |
| Q2 2022 | $14,000 | -41.7% | 1,000 | 0.0% | 0.00% | – |
| Q1 2022 | $24,000 | +4.3% | 1,000 | 0.0% | 0.00% | – |
| Q4 2021 | $23,000 | -34.3% | 1,000 | -53.1% | 0.00% | – |
| Q3 2021 | $35,000 | -32.7% | 2,130 | 0.0% | 0.00% | – |
| Q2 2021 | $52,000 | -5.5% | 2,130 | 0.0% | 0.00% | – |
| Q1 2021 | $55,000 | -46.1% | 2,130 | -43.9% | 0.00% | -100.0% |
| Q1 2019 | $102,000 | +67.2% | 3,800 | 0.0% | 0.00% | – |
| Q4 2018 | $61,000 | -22.8% | 3,800 | 0.0% | 0.00% | -100.0% |
| Q3 2018 | $79,000 | +36.2% | 3,800 | 0.0% | 0.00% | – |
| Q2 2018 | $58,000 | -31.8% | 3,800 | 0.0% | 0.00% | -100.0% |
| Q1 2018 | $85,000 | -40.1% | 3,800 | -19.1% | 0.00% | 0.0% |
| Q4 2017 | $142,000 | -19.8% | 4,700 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $177,000 | +35.1% | 4,700 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $131,000 | -19.1% | 4,700 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $162,000 | -20.2% | 4,700 | -33.3% | 0.00% | -50.0% |
| Q4 2016 | $203,000 | -42.0% | 7,045 | -35.9% | 0.00% | -33.3% |
| Q3 2016 | $350,000 | +8.0% | 10,993 | +10.0% | 0.00% | 0.0% |
| Q2 2016 | $324,000 | -9.0% | 9,992 | -21.4% | 0.00% | 0.0% |
| Q1 2016 | $356,000 | +17.5% | 12,715 | +49.7% | 0.00% | 0.0% |
| Q4 2015 | $303,000 | +94.2% | 8,492 | +80.0% | 0.00% | +200.0% |
| Q3 2015 | $156,000 | -20.8% | 4,718 | +0.4% | 0.00% | -50.0% |
| Q2 2015 | $197,000 | +26.3% | 4,700 | -1.7% | 0.00% | +100.0% |
| Q1 2015 | $156,000 | -46.2% | 4,782 | -47.7% | 0.00% | -50.0% |
| Q4 2014 | $290,000 | +24.5% | 9,149 | -2.8% | 0.00% | 0.0% |
| Q3 2014 | $233,000 | +301.7% | 9,408 | +268.7% | 0.00% | +100.0% |
| Q2 2014 | $58,000 | -15.9% | 2,552 | -10.0% | 0.00% | 0.0% |
| Q1 2014 | $69,000 | +72.5% | 2,834 | +77.1% | 0.00% | – |
| Q4 2013 | $40,000 | – | 1,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |